Filters
Technology
Platform
GSE2034
Homo sapiens
285 Downloadable Samples
Affymetrix Human Genome U133A Array (hgu133a)
Description
This series represents 180 lymph-node negative relapse free patients and 106 lymph-node negate patients that developed a distant metastasis.
Publication Title
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Sample Metadata Fields
No sample metadata fields
View Samples- Homo sapiens
- 136 Downloadable Samples
- Affymetrix Human Genome U133A Array (hgu133a)
Description
Classification of tamixifen-treated breast cancer patients into high and low risk groups using the 76-gene signature
Publication Title
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Sample Metadata Fields
No sample metadata fields
View Samples- Homo sapiens
- 130 Downloadable Samples
- Affymetrix Human Genome U133A Array (hgu133a)
Description
Gene signatures were derived to separate high risk patients from low risk ones..
Publication Title
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
Sample Metadata Fields
No sample metadata fields
View Samples- Homo sapiens
- 104 Downloadable Samples
- Affymetrix Human Genome U133A Array (hgu133a)
Description
A number of breast or colon specific genes predictive of the relapse status were used in comparing the outcome from matched fresh frozen and stored in RNAlater preservative.
Publication Title
Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative.
Sample Metadata Fields
No sample metadata fields
View Samples- Homo sapiens
- 58 Downloadable Samples
- Affymetrix Human Genome U133A Array (hgu133a)
Description
Gene signatures were derived to separate responders from nonresponders by tipifarnib treatment.
Publication Title
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Sample Metadata Fields
Sex, Age
View Samples- Homo sapiens
- 33 Downloadable Samples
- Affymetrix Human Genome U133A Array (hgu133a)
Description
Currently there is no method available to predict response to farnesyltransferase inhibitors (FTI). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib, in older adults with previously untreated acute myeloid leukemia (AML). The RASGRP1:APTX gene expression ratio was found to predict response to tipifarnib with the greatest accuracy. This two-gene ratio was validated by quantitative PCR (QPCR) in the newly diagnosed AML cohort. We further demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a negative predictive value (NPV) and positive predictive value (PPV) of 92% and 28%, respectively (odds ratio of 4.4). The classifier also predicted for improved overall survival (154 vs 56 days, p = 0.0001), which was shown to be independent of other prognostic factors including a previously described gene expression classifier predictive of overall survival. Therefore, these data indicate that a two-gene expression assay may have utility in categorizing a population of AML patients who are more likely to respond to tipifarnib.
Publication Title
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Sample Metadata Fields
Sex, Age, Disease
View Samples